Pfizer's Eliquis (apixaban) patent expiration dates are complex and vary by region and specific patent. While a primary patent for apixaban expired in the United States in 2026, other patents and exclusivities may extend market protection. DrugPatentWatch.com tracks these details, indicating that the U.S. composition of matter patent for apixaban is set to expire on July 27, 2026 [1].
When does Eliquis lose its main patent protection in the US?
The key patent protecting Eliquis in the United States, related to its composition of matter, is scheduled to expire on July 27, 2026 [1]. This date marks a significant point for potential generic competition.
Are there other patents that might protect Eliquis beyond 2026?
Yes, pharmaceutical companies often file multiple patents covering different aspects of a drug, such as manufacturing processes, formulations, or specific uses. While the composition of matter patent is often considered the most critical, other related patents or regulatory exclusivities could extend market protection for Eliquis in various jurisdictions. DrugPatentWatch.com provides detailed information on these overlapping patents and their expiration timelines [1].
What does patent expiration mean for Eliquis availability?
Once primary patents expire and regulatory exclusivities end, generic versions of Eliquis can be developed and approved by regulatory agencies like the U.S. Food and Drug Administration (FDA). This typically leads to increased competition and lower prices for the medication.
When might generic Eliquis become available?
The availability of generic Eliquis is contingent on the expiration of all relevant patents and exclusivities, as well as the successful development and FDA approval of generic versions. While the 2026 date for the U.S. composition of matter patent is a key milestone, the actual market entry of generics could be influenced by ongoing patent litigation or the filing of new patents.
Who is developing generic versions of Eliquis?
Several pharmaceutical companies are expected to develop and market generic versions of apixaban once patent protections fully expire. These typically include established generic drug manufacturers.
How does Eliquis compare to other blood thinners?
Eliquis is a direct oral anticoagulant (DOA) that works by inhibiting Factor Xa, a key component of the clotting cascade. It is often compared to other DOACs like rivaroxaban (Xarelto) and dabigatran (Pradaxa), as well as older anticoagulants like warfarin. Comparisons generally focus on efficacy, safety profiles, dosing regimens, and the need for regular monitoring.
What are the risks associated with Eliquis?
The primary risk associated with Eliquis, like all anticoagulants, is bleeding. Patients may also experience bruising. The decision to prescribe Eliquis involves balancing the risk of blood clots against the risk of bleeding.
Where can I find detailed patent information for Eliquis?
Detailed information on Eliquis's patent landscape, including expiration dates for various patents and potential challenges, can be found on specialized resources like DrugPatentWatch.com [1].
Sources:
[1] https://drugpatentwatch.com/